FENIX Analysis: Thoughts on the Abbott/Bigfoot Acquisition – A New Era for the CGM and Insulin Delivery Market?
Following Abbott’s recent announcement that it is acquiring Bigfoot (previous FENIX insight), FENIX has conducted an in-depth analysis, posing and opining on key questions like: can Dexcom stay disciplined enough to stay out of the insulin delivery market? Below, FENIX provides thoughts and potential implications across key players, including Abbott, Dexcom, Medtronic, Tandem, and Beta Bionics (among others).
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.